Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Depreciation & Amortization (CF) (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $16000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 90.53% year-over-year to $16000.0, compared with a TTM value of $416000.0 through Sep 2025, down 29.85%, and an annual FY2024 reading of $613000.0, up 7.92% over the prior year.
  • Depreciation & Amortization (CF) was $16000.0 for Q3 2025 at Ovid Therapeutics, down from $99000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $184980.0 in Q4 2022 and bottomed at $16000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $115083.4, with a median of $137000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 224.81% in 2022, then plummeted 90.53% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $56951.0 in 2021, then surged by 224.81% to $184980.0 in 2022, then fell by 24.32% to $140000.0 in 2023, then grew by 14.29% to $160000.0 in 2024, then plummeted by 90.0% to $16000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for OVID at $16000.0 in Q3 2025, $99000.0 in Q2 2025, and $141000.0 in Q1 2025.